Aandeel 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen SciClone Pharmaceuticals (Holdings) Limited

Aandelen

6600

KYG4271B1023

Beurs gesloten - Hong Kong S.E.
Andere beurzen
 10:08:16 24-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
17,98 HKD -0,11% Intraday-grafiek van SciClone Pharmaceuticals (Holdings) Limited -0,11% +29,17%
01/04 SciClone Pharmaceuticals boekt 31% meer winst in 2023 MT
28/03 Sciclone Pharmaceuticals (Holdings) Limited kondigt wijzigingen in de leiding aan CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
Sciclone Pharmaceuticals Limited Announces Executive Changes
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
SciClone Commercially Launches Neuroblastoma Treatment in China
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 6600
  4. Nieuws SciClone Pharmaceuticals (Holdings) Limited
  5. Andere talen